The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

VJVirtual | Management of Irish ALK+ NSCLC patients with brigatinib

Name: Management of Irish ALK+ NSCLC patients with brigatinib
Uploaded: 2020-11-04T00:00:00Z
Duration: 1 min 42 s
Description: Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, discusses the impact of the changes of brigatinib reimbursement in Irish patients with ALK+ non-small cell cancer (NSCLC), based on the results of the Phase III ALTA-1L study (NCT02737501). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

Jarushka Naidoo • 4 Nov 2020

Lung Cancer Non-Small Cell Lung Cancer Brigatinib Crizotinib

ALTA-1L

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, discusses the impact of the changes of brigatinib reimbursement in Irish patients with ALK+ non-small cell cancer (NSCLC), based on the results of the Phase III ALTA-1L study (NCT02737501). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)